The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET–CT
Trond Velde Bogsrud(Mayo Clinic), Val J. Lowe(Mayo Clinic), Gregory A. Wiseman(Mayo Clinic), Scott E. Strome(Northwestern Medicine Lake Forest Hospital), Dimitrios Karantanis(Mayo Clinic), Ian Hay(University of Tasmania), Jan L. Kasperbauer(Mayo Clinic), Douglas A. Collins(Mayo Clinic), Mark A. Nathan(Mayo Clinic), Carl C. Reading(University of Minnesota Rochester), Brian P. Mullan(Mayo Clinic)
Cited by 107
Related Papers
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
|Proceedings of the National Academy of Sciences|2004|767
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699
Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|548